Literature DB >> 20521252

Overexpression of carbonic anhydrase XII in tissues from resectable non-small cell lung cancers is a biomarker of good prognosis.

Marius I Ilie1, Véronique Hofman, Cécile Ortholan, Reda El Ammadi, Christelle Bonnetaud, Katia Havet, Nicolas Venissac, Jerôme Mouroux, Nathalie M Mazure, Jacques Pouysségur, Paul Hofman.   

Abstract

The pattern of protein expression in tumors is under the influence of nutrient stress, hypoxia and low pH, which determines the survival of neoplastic cells and the development of tumors. Carbonic anhydrase XII (CAXII) is a transmembrane enzyme that catalyzes the reversible hydration of cell-generated carbon dioxide into protons and bicarbonate. Hypoxic conditions activate its transcription and translation and enhanced expression is often present in several types of tumors. The aim of our study was to assess the prognostic significance of CAXII tumor tissues expression in patients with NSCLC. Five hundred fifty-five tumors were immunostained for CAXII on tissue microarrays (TMA) and the results were correlated with clinicopathological parameters and outcome of patients. CAXII overexpression was present in 105/555 (19%) cases and was associated with tumors of lower grade (p = 0.015) and histological type (p < 0.001), being significantly higher in squamous cell carcinoma. High CAXII expression correlated with better overall and disease-specific survival of patients with resectable NSCLC in univariate (p < 0.001) and multivariate survival analyses (p < 0.001). In conclusion, this is the first study demonstrating that a high CAXII tumor tissue expression evaluated on TMAs is related to a better outcome in a large series of patients with resectable NSCLC.
Copyright © 2010 UICC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20521252     DOI: 10.1002/ijc.25491

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  29 in total

Review 1.  Carbonic anhydrases as disease markers.

Authors:  Sabina Zamanova; Ahmed M Shabana; Utpal K Mondal; Marc A Ilies
Journal:  Expert Opin Ther Pat       Date:  2019-06-17       Impact factor: 6.674

2.  Carbonic anhydrases II, IX, and XII in Barrett's esophagus and adenocarcinoma.

Authors:  Minna Nortunen; Heikki Huhta; Olli Helminen; Seppo Parkkila; Joonas H Kauppila; Tuomo J Karttunen; Juha Saarnio
Journal:  Virchows Arch       Date:  2018-07-31       Impact factor: 4.064

3.  TFAP2C regulates carbonic anhydrase XII in human breast cancer.

Authors:  Christopher M Franke; Vivian W Gu; Benjamin G Grimm; Victoria C Cassady; Jeffrey R White; Ronald J Weigel; Mikhail V Kulak
Journal:  Oncogene       Date:  2019-10-21       Impact factor: 9.867

Review 4.  Targeting carbonic anhydrase IX and XII isoforms with small molecule inhibitors and monoclonal antibodies.

Authors:  Mateusz Kciuk; Adrianna Gielecińska; Somdutt Mujwar; Mariusz Mojzych; Beata Marciniak; Rafał Drozda; Renata Kontek
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

Review 5.  Carbonic anhydrase XII inhibition overcomes P-glycoprotein-mediated drug resistance: a potential new combination therapy in cancer.

Authors:  Kathryn F Tonissen; Sally-Ann Poulsen
Journal:  Cancer Drug Resist       Date:  2021-06-19

6.  Advances in Anti-Cancer Drug Development Targeting Carbonic Anhydrase IX and XII.

Authors:  Mam Y Mboge; Robert McKenna; Susan C Frost
Journal:  Top Anticancer Res       Date:  2015

Review 7.  Carbonic anhydrase XII functions in health and disease.

Authors:  Abdul Waheed; William S Sly
Journal:  Gene       Date:  2017-04-19       Impact factor: 3.688

8.  In papillary thyroid carcinoma, TIMP-1 expression correlates with BRAF (V600E) mutation status and together with hypoxia-related proteins predicts aggressive behavior.

Authors:  Marius I Ilie; Sandra Lassalle; Elodie Long-Mira; Véronique Hofman; Joséphine Zangari; Gilles Bénaim; Alexandre Bozec; Nicolas Guevara; Juliette Haudebourg; Isabelle Birtwisle-Peyrottes; José Santini; Patrick Brest; Paul Hofman
Journal:  Virchows Arch       Date:  2013-07-27       Impact factor: 4.064

9.  A three gene-based risk score predicts prognosis of resected non-small-cell lung cancer.

Authors:  Kun Liu; Hong-Lin Chen; Ming-Ming Gu; Qing-Sheng You
Journal:  Int J Clin Exp Pathol       Date:  2015-12-01

10.  CAXII Is a sero-diagnostic marker for lung cancer.

Authors:  Makoto Kobayashi; Toshihide Matsumoto; Shinichiro Ryuge; Kengo Yanagita; Ryo Nagashio; Yoshitaka Kawakami; Naoki Goshima; Shi-Xu Jiang; Makoto Saegusa; Akira Iyoda; Yukitoshi Satoh; Noriyuki Masuda; Yuichi Sato
Journal:  PLoS One       Date:  2012-03-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.